New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018) - 102204

Spotlight
Video

New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)

BeaconMedIC has 21 videos Subscribe Here

Loading........
Description: Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology.
Shared By : BeaconMedIC
Posted on : 12/08/17
Added : 1 month ago



More From BeaconMedIC

Nothing found.